Beactica Announces Drug Discovery Collaboration With Arrow Therapeutics (14 Nov 2007) agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its novel characterisation technology at selected Arrow compounds against a confidential target. "We are very pleased to be working with Arrow" said Beactica's...
AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities (05 Feb 2007)
AstraZeneca announced an agreement to acquire Arrow Therapeutics Ltd... of anti-viral therapies. The total share capital of Arrow Therapeutics... programmes developed by Arrow Therapeutics, include several different approaches...
Arrow Therapeutics selects a further Hepatitis C compound A-689 (17 Jan 2007) Arrow Therapeutics has announced that a further Hepatitis C compound, A-689... Arrow's broad approach to the NS5a target to enter development. November 2006 saw Arrow's first Hepatitis C compound, A-831, enter Phase I trials. Both compounds...
Arrow Therapeutics HCV Compound Enters Phase I (28 Nov 2006) Arrow Therapeutics, a London based antiviral drug discovery and development... is the first compound from Arrow's approach to the NS5a target. A further Arrow compound..., is expected to enter preclinical development shortly. Arrow Therapeutics Ltd...
Top